ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Netherlands Cancer Institute at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Netherlands Cancer Institute takes part in 36 sessions at ESMO 2026 in Madrid. Its program focuses on immunotherapy and treatment decisions across cancer types, including breast cancer and melanoma. It examines whether immune-based treatment can help preserve organs in skin cancer and how biomarkers can guide treatment.

OrganizationESMO 2026 Attendance
Netherlands Cancer Institute
Amsterdam, Netherlands
Cancer centre & hospital
Cancer research institute with its own cancer hospital in Amsterdam, Netherlands.
Poster
Fri Oct 23
13:00–15:00
A phase 2 clinical study to assess efficacy of induction carboplatin/paclitaxel + pembrolizumab for locoregionally advanced penile cancer: PRIAM
ePoster session 6
Genitourinary cancersSarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
13:00–15:00
Clinical implementation of a robust IFN-gamma gene signature pipeline for treatment stratification in stage III melanoma
ePoster session 13
Melanoma & skin cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Chair
Fri Oct 23
13:30–15:00
Proffered paper: Investigational immunotherapy
with Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Poster
Fri Oct 23
15:15–16:00
Lung cancer subtyping using cell-free DNA fragmentomes and protein biomarkers
Friday Poster Display session 2
Lung & thoracic cancersBiomarkers & precision oncology
Chair
Fri Oct 23
16:15–17:45
Raising the bar for tumor-agnostic studies
with Vall d'Hebron Institute of Oncology (VHIO)
Biomarkers & precision oncology
Talk
Fri Oct 23
16:45–17:00
Tumor agnostic drug repurposing trials: Boost or brake?
Raising the bar for tumor-agnostic studies
Biomarkers & precision oncology
Chair
Sat Oct 24
08:30–10:00
Chair
Sat Oct 24
10:15–11:30
Multidisciplinary insights for effective care in gynaecological sarcomas
with The Royal Marsden
Sarcoma, CNS, head & neck and rare cancers
Talk
Sat Oct 24
10:15–10:30
Talk
Sat Oct 24
10:15–10:35
Presentation by Expert
Optimization strategies of immunotherapy in potentially curative solid tumours: Scientific and clinical rationale in decision making
Talk
Sat Oct 24
10:15–10:35
Treating for two: Immunotherapy, targeted therapy, and other treatments in pregnancy
Challenging clinical scenarios in melanoma and skin cancers
Melanoma & skin cancers
Talk
Sat Oct 24
10:50–11:05
Local treatment: Surgery (LMS/HGUS/ESS)
Multidisciplinary insights for effective care in gynaecological sarcomas
Sarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
Innate lymphocytes kickstart immunotherapy responses in colon cancer
Saturday Poster Display session 4
Gastrointestinal cancers
Poster
Sat Oct 24
12:00–12:45
Neoadjuvant anti-PD1 without chemotherapy in early-stage luminal B breast cancer
Saturday Poster Display session 1
Breast cancer
Poster
Sat Oct 24
12:00–12:45
Neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma – MARIANE
Saturday Poster Display session 4
Melanoma & skin cancers
Poster
Sat Oct 24
12:00–12:45
Neoadjuvant ipilimumab plus nivolumab (IPI+NIVO) after adjuvant PD-1 blockade in resectable stage III melanoma
Saturday Poster Display session 4
Melanoma & skin cancers
Poster
Sat Oct 24
12:00–12:45
The addition of Carboplatin to neoadjuvant chemotherapy in stage III triple-negative breast cancer
Saturday Poster Display session 3
Breast cancer
Poster
Sat Oct 24
12:00–12:45
Week 6 interferon-gamma signature identifies melanoma patients at high risk of recurrence to neoadjuvant immunotherapy
Saturday Poster Display session 4
Melanoma & skin cancersBiomarkers & precision oncology
Talk
Sat Oct 24
12:19–12:26
Table 8
Mentor the Mentor session
Talk
Sat Oct 24
14:45–15:05
Optimising systemic therapy and sequence for stage I TNBC
Optimising treatment for triple negative early breast cancer
Breast cancer
Chair
Sat Oct 24
14:45–16:15
Abstract
Sat Oct 24
17:06–17:18
Invited Discussant LBA2
Presidential Symposium I
Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers
Chair
Sun Oct 25
10:15–11:45
Proffered paper: Policy
with Centre Léon Bérard
Talk
Sun Oct 25
10:35–10:55
Novel immunotherapy; CAR-T, Bispecific antibodies, New ICIs
Emerging new systemic therapies for RCC
Genitourinary cancers
Abstract
Sun Oct 25
11:33–11:45
Invited Discussant 3314O, 3315O and LBA86
Proffered paper: Policy
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Neoadjuvant botensilimab plus balstilimab in MMR deficient colorectal cancer: Results from the NEOASIS study
Sunday Poster Display session 4
Gastrointestinal cancers
Poster
Sun Oct 25
12:00–12:45
Neoadjuvant nivolumab plus relatlimab or nivolumab plus IL-8 in pMMR colon cancer
Sunday Poster Display session 5
Gastrointestinal cancers
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Validation of deep learning-based TIL assessment in young patients with node-negative HER2-positive breast cancer
Sunday Poster Display session 2
Breast cancerBiomarkers & precision oncology
Chair
Sun Oct 25
16:30–18:00
Peri-operative management of urothelial cancer
with University of Cambridge
Genitourinary cancers
Chair
Sun Oct 25
16:30–18:00
Pillars of personalised cancer prevention: The breast cancer case
with Vall d'Hebron University Hospital
Breast cancer
Abstract
Mon Oct 26
09:29–09:34
Abstract
Mon Oct 26
10:20–10:25
4250RO - High affinity FcγR3A germline SNP impairs outcome upon anti-PD1 in melanoma
Rapid oral 2: Basic science and translational research
Biomarkers & precision oncology
Poster
Mon Oct 26
12:00–12:45
Health-related quality of life in intra-abdominal and retroperitoneal sarcoma patients: An international multicentre study
Monday Poster Display session 6
Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersNursing & supportive care
Chair
Mon Oct 26
14:45–16:15
Proffered paper 2: Basic science and translation research
with Aarhus University Hospital
Biomarkers & precision oncology
Chair
Mon Oct 26
14:45–16:15
Rapid oral: Prevention, early detection and intervention
with Medical University of Vienna, MD Anderson Cancer Center
Abstract
Mon Oct 26
14:55–15:07
Invited Discussant 1149RO, 3442RO and 3883RO
Rapid oral: Prevention, early detection and intervention
Talk
Mon Oct 26
15:25–15:45
How to integrate new imaging techniques in the clinic
Incorporation of biomarkers for early breast cancer
Breast cancer
Abstract
Mon Oct 26
15:49–16:01
Invited Discussant 4240O and 4242O
Proffered paper 2: Basic science and translation research
Biomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Netherlands Cancer Institute

Tell us what you sell and we’ll find the people at Netherlands Cancer Institute most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction